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ABSTRACT: Background. Bony non-unions arising in the aftermath of
collateral radiation injury are commonly managed with vascularized free
tissue transfers. Unfortunately, these procedures are invasive and
fraught with attendant morbidities. This study investigated a novel, alter-
native treatment paradigm utilizing adipose-derived stem cells (ASCs)
combined with angiogenic deferoxamine (DFO) in the rat mandible.
Methods. Rats were exposed to a bioequivalent dose of radiation and
mandibular osteotomy. Those exhibiting non-unions were subsequently
treated with surgical debridement alone or debridement plus combina-
tion therapy. Radiographic and biomechanical outcomes were assessed
after healing.
Results. Significant increases in biomechanical strength and radio-
graphic metrics were observed in response to combination therapy (p <
.05). Importantly, combined therapy enabled a 65% reduction in persist-
ing non-unions when compared to debridement alone.
Conclusion. We support the continued investigation of this promising
combination therapy in its potential translation for the management of
radiation-induced bony pathology. VC 2015 Wiley Periodicals, Inc. Head
Neck 38: E837–E843, 2016
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adipose-derived stromal cell, deferoxamine
INTRODUCTION
The current arsenal for managing non-unions in previously
irradiated bone involves the removal of necrotic tissue and
vascularized free tissue transfers. These surgical proce-
dures are complex, arduous, and introduce significant
donor site morbidity.1–6 Further, there are no accepted
reconstructive options to turn to once autologous tissue
transplantation fails. Efficacious treatment alternatives for
managing these events are therefore highly sought after.
Radiation exerts its damaging effects on bone through
mechanisms of vascular diminution, depletion of cellular
volume, and attenuation of existing osteocyte func-
tion.7–11 Previously, we have utilized a mandibular rat
model of radiation-induced pathologic fracture healing to
investigate these ravaging effects. We demonstrated dimin-
ished metrics of vascularity, osteocyte viability, callus min-
eralization, and biomechanical strength.12–14 Further, we
evidenced a reproducible non-union rate of 75% to
80%.12–14 The purpose of our current investigation was to
address the mechanisms of vascular diminution and deple-
tion of viable cells at the site of non-union by therapeuti-
cally reestablishing vascularity and replacing necrotic tissue
with viable progenitor cells. To do this, we utilize adipose-
derived stem cells (ASCs) in combination with angiogenic
deferoxamine (DFO) in our established animal model.
ASCs represent a multipotent, abundant stromal cell
type with the demonstrated capacity to differentiate along
an osteogenic lineage through stimulation of the bone
morphogenic protein pathway, making them suitable for
filling bony defects.15–25 DFO is an iron-chelating com-
pound currently on formulary for treating patients with
transfusion-related iron overload.26 It has also been shown
to invoke angiogenic responses when utilized in minute,
intermittent doses in a localized environment.27–29 Our
laboratory has since extended the use of this powerful
strategy to improve pathologic bone healing after radia-
tion injury in the rat mandible.12–14,26
We hypothesize that the combined utility of ASCs and
DFO will rescue non-unions arising in the aftermath of
radiotherapy, evidencing enhanced metrics of radio-
graphic mineralization and biomechanical strength.
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MATERIALS AND METHODS
Experimental design
Animal experimentation was conducted in accordance
with the guidelines published in the Guide for the Care
and Use of Laboratory Animals: Eighth Edition, ISBN-
10: 0-309-15396-4. Protocols were approved by the Uni-
versity of Michigan’s Committee for the Utilization and
Care of Animals before implementation. Forty-eight adult
male Lewis rats (range, 300–350 g) were obtained
through the University of Michigan’s Unit for Laboratory
Animal Medicine. All animals were caged in a restricted,
pathogen-free facility and maintained on a 12-hour light/
dark schedule. Before handling and radiation, a 7-day
acclimation period was allowed. Thirty-six rats were sub-
jected to a human equivalent dose of radiation (HEDR)
and osteotomy surgery, followed by external fixation and
a subsequent 40-day fracture healing period. After radio-
graphic assessment, those exhibiting non-unions (n 5 30)
were further subdivided randomly into 2 groups for a sec-
ond surgery: surgical debridement (n 5 15) and surgical
debridement with combination therapy (n 5 15). Defects
of animals in the combination therapy group were
implanted with ASC-loaded scaffolds, and these animals
received postoperative DFO injections. All animals were
then allowed a second 40-day healing period after which
the animals were euthanized and their mandibles har-
vested for further analysis.
Animal radiation protocol
All radiation procedures were conducted in the Irradia-
tion Core at the University of Michigan. After transient
induction of anesthesia with an oxygen/isoflurane mix-
ture, left hemimandibles were irradiated using a Philips
RT250 orthovoltage unit (250 kV X-rays, 15 mA; Kim-
tron Medical, Woodbury, CT), which delivers ionizing
radiation through a filtered system to a specified region
of interest (ROI). Our selected ROI spans a 2-mm dis-
tance posterior to the third molar and correlates to the
anatomic site of the osteotomy. Lead shielding was pro-
vided to ensure localized delivery and protection of sur-
rounding tissues. A previously described HEDR
developed with the guidance of the Department of Radia-
tion Oncology at the University of Michigan was utilized.
Briefly, a fractionated dose of 7 Gy per day was adminis-
tered over 5 days for a total of 35 Gy. This is comparable
to 70 Gy in human mandibular high-dose radiotherapy.
This dose was designed to predictably replicate patholo-
gies analogous to those observed in the setting of clini-
cally advanced mandibular osteoradionecrosis, while
taking the diminutive size of the mandible and surround-
ing tissues into consideration.30–32
Perioperative care
Gentamicin (30 mg/kg SQ) was administered once
before surgery and twice postoperatively. To ensure
adequate analgesia, hydration, and anesthesia, rats were
delivered buprenorphine (0.15 mg/kg SQ) and subcutane-
ous Lactated Ringer’s solution (25 cc/kg SQ), and then
anesthetized using an inhalational oxygen/isoflurane mix-
ture throughout the surgical procedure. Postoperatively,
animals were placed on warming blankets and monitored
for heart and respiratory rates. Postoperative analgesia
with buprenorphine was continued twice daily through
postoperative day 4, and as needed thereafter. Weight
gain, porphyrin staining, and nutritional intake were
assessed to determine the need for continued analgesia.
Osteotomy and fixator placement
After standard preparation and draping, a 2-cm midline
incision was performed ventrally from the anterior sub-
mentum to the neck crease. A custom titanium fixator
device was placed, as previously described.33 After stabi-
lization of the fixator, a vertical osteotomy was created
using a reciprocating blade (Stryker, Kalamazoo, MI)
directly behind the third molar on the left hemimandible.
After reduction of the osteotomy edges, wounds were irri-
gated, hemostasis verified, and incisions were closed in
layers. Four hours after osteotomy, the fixator device was
set to a 2 mm fixed distance and a 40-day healing period
was allowed before radiographic evaluation.
Adipose-derived stromal cell culturing
ASCs were isolated from the inguinal fat pads of 12
adult male isogenic Lewis rats, as previously described.34
Rats were euthanized with inhalational isoflurane, and
then fat pads were cautiously dissected from donor rats,
washed sequentially in serial dilutions of betadine, and
then mechanically digested in Hanks Balanced Salt solu-
tion (no calcium, no magnesium; Life Technologies,
Grand Island, NY). The minced pads were exposed to
0.075% collagenase A (C5894; Sigma–Aldrich, St. Louis,
MO) while shaken briskly in a 378C water bath for 30
minutes. Dulbecco’s Modified Eagle Medium (DMEM;
Sigma–Aldrich) with 10% fetal bovine serum (FBS; Life
Technologies) was then used to neutralize the collagenase
A, and the cell suspension was passed through a 100-lm
cell strainer, ensuring removal of the larger undigested
tissue. Cells were centrifuged at 1000 rpm for 5 minutes,
and the cell pellet was resuspended in a fresh growth
medium (DMEM with 10% FBS, 100 IU/mL penicillin,
and 100 IU/mL streptomycin). Cells less than passage 3
were utilized in stem cell implantation during a second
surgery.
Adipose-derived stromal cell scaffold preparation
Each gelatin sponge (Surgifoam; Ethicon, Somerville,
NJ) was designed to be a 2 3 9 3 2-mm rectangle to
match the maximum critical size defect of our fracture
gap. The sponges were pre-wetted in the complete
medium (DMEM with 10% FBS, 100 IU/mL penicillin,
and 100 IU/mL streptomycin) and air bubbles were
removed by applying gentle pressure on the sponge
between 2 pieces of sterile filter paper. Two million
ASCs were collected and suspended in 50 lL of collagen
(2.5 mg/mL, rat tail collagen, type I; BD Biosciences,
Franklin Lakes, NJ), and loaded onto each sponge using
capillary action. Previous experiments have shown via
direct cell counts (Coulter counter, model ZBI; Coulter
Electronics, Hialeah, FL) of the residual suspension after
removal of the gelatin sponge, that when utilizing this
procedure, greater than 95% of the cells entered the
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sponges.35 After loading the sponges with the cells, all
vehicles were incubated at 378C for 30 minutes before
implantation.
Debridement, adipose-derived stem cell implantation,
and deferoxamine administration
After the initial 40-day healing period, mandibles were
assessed radiographically (MX20; Faxitron X-Ray, Lin-
colnshire, IL; Figure 1). Animals exhibiting unions (n 5
6) were excluded from the remainder of the study. Rats
displaying non-unions were randomly divided into 2
groups. Both groups (n 5 15/group) underwent surgical
debridement, consisting of sharp dissection, and removal
of necrotic soft tissue by scalpel. The combination ther-
apy group received implantation of ASC-loaded gelatin
sponges into the fracture gap before masseter closure
(Figure 2). The combination therapy group was then sub-
jected to localized injections of DFO (200 lM; 300 lL)
directly into the fracture gap by palpating the defect
through the overlying skin. These injections were admin-
istered every other day from postoperative days 4 to 12,
for a total of 5 doses, as previously described, in order to
coincide with the peak of angiogenesis in a murine frac-
ture model.12–14,26–29,36,37 After a second 40-day healing
period, animals were euthanized by isoflurane overdose
followed by thoracotomy, and left hemimandibles were
dissected en bloc for outcome testing.
Micro-CT analysis
Dissected mandibles were assessed for incidence of
bony union, which was clinically defined as bone bridg-
ing and absence of movement across the fracture site
upon manipulation. Micro-CT images were obtained using
80 kVp, 80 mA, and 1100 ms exposures. Three hundred
ninety-two projections were taken at a 45-micron voxel
size for bone analysis. GE’s Microview 2.2 software was
used to generate the ROI and derive metrics of total vol-
ume, bone volume, bone volume fraction (BVF), tissue
mineral density (TMD), and bone mineral density (BMD).
Biomechanical testing
After imaging, both the anterior and posterior ends of
the mandibles were potted in bismuth and loaded to fail-
ure in uniaxial monotonic tension at 0.5 mm/s using a
servohydraulic testing machine (858 Minibiox II; MTS
Systems Corporation, Eden Prairie, MN). Crosshead dis-
placement was recorded by using an external variable dif-
ferential transducer (Lucas Schavitts, Hampton, VA), and
load data were collected with a 100-lb load cell (Senso-
tec, Columbus, OH). Data were sampled at 200 Hz on a
TestStar system (TestStar IIs System version 2.4; MTS
FIGURE 1. Faxitron confirmation of established non-union (out-
lined in red) in the left hemimandible after an initial 40-day heal-
ing period.
FIGURE 2. Implantation of the adipose-derived stem cells (ASCs) scaffold into the fracture site. The rat is lying on his dorsum, with the inferior bor-
der of the left mandible exposed.
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Systems Corporation, Minneapolis, MN). Load-
displacement curves were analyzed for whole bone yield
load, failure energy, ultimate load, failure load, and elas-
tic energy, using custom computational code (MATLAB
7.11; Mathworks, Natick, MA).
Statistical analysis
An independent samples t test was used for analyzing
both the mineralization and biomechanical data (SPSS
version 16.0; SPSS, Chicago, IL). Results were accepted
as statistically significant at a value of p < .05.
RESULTS
Micro-CT results
Radiomorphometric analysis of the ROI indicated sig-
nificant differences in mineralization parameters between
the combination therapy group and surgical debridement
group (Table 1). Specifically, the combination therapy
group yielded significantly higher values for BVF (p 5
.034), BMD (p 5 .038), and TMD (p 5 .013) as com-
pared to the surgical debridement group. These enhanced
metrics suggest that the combination therapy facilitates
more robust mineralization in the healing mandible when
compared to surgical debridement alone (Figure 3).
Biomechanical testing results
Metrics for biomechanical strength paralleled the radio-
morphometric data, exhibiting significantly higher values
for the combination therapy group than the surgical
debridement group (Table 2). Mandibles exposed to com-
bination therapy evidenced significantly greater values for
whole bone yield load (p 5 .015) and failure energy (p
5 .026). Additional differences trending toward statistical
significance further suggested enhanced biomechanical
integrity in the treatment group. These trending differen-
ces included ultimate load (p 5 .066), failure load (p 5
.095), and elastic energy (p 5 0.057). These biomechani-
cal data imply that the introduction of this angiogenic and
stem cell based therapy enhances the tensile strength of
healing mandibles above those receiving only surgical
debridement.
Bony union results
Perhaps most clinically significant, the combination
therapy group demonstrated a 65% improvement in the
remediation of non-unions compared with the surgical
debridement group. Specifically, the combination therapy
group displayed a 7% incidence of non-union, whereas
the surgical debridement group exhibited a 20% incidence
of non-union.
DISCUSSION
Despite advancements in the delivery of radiotherapy
for head and neck cancer, advanced osteoradionecrosis
and associated non-unions still occur.7,38,39 Furthermore,
there remains a grave disparity between the complex,
severe, and corrosive collateral damage imposed by radio-
therapy and the limitations in our current diagnostic and
reconstructive armaments for managing these pernicious
side effects. The purpose of this experiment was to inves-
tigate a therapeutic strategy designed to restore both the
cellularity and vascularity at the site of mandibular non-
union in rat mandibles exposed to radiation injury. We
posited that the cellular replenishment afforded by ASCs,
in combination with the angiogenic stimulus of DFO,
would rescue non-unions arising in the aftermath of radio-
therapy, evidencing enhanced metrics of radiographic
mineralization and biomechanical strength.
We previously established diminished metrics of vascu-
larity, osteocyte viability, callus mineralization, and bio-
mechanical strength in a rat model of radiation-induced
mandibular pathologic fracture healing.12–14 We further
evidenced a reproducible non-union rate of 75% to 80%
because of the administration of an HEDR.12–14 The pur-
pose of our previous studies concerned the prevention of
radiation-induced bone-related pathologies, such as non-
union with the use of DFO therapy. DFO exerts its angio-
genic function by stimulating the hypoxia inducible factor
TABLE 1. Micro-CT radiomorphometrics for bone volume fraction, bone
mineral density, and tissue mineral density.
Debridement ASCs 1 DFO p value
BVF 0.78 6 0.069 0.85 6 0.073 .034*
BMD, mg/cc 665.64 6 56.23 722.08 6 65.20 .038*
TMC, mg 16.18 6 4.14 20.42 6 3.29 .013*
Abbreviations: ASCs, adipose-derived stem cells; DFO, deferoxamine; BVF, bone volume frac-
tion; BMD, bone mineral density; TMD, tissue mineral density.
Means 6 SDs for micro-CT callus mineralization metrics for each group. The p values were
also given for independent t tests between the groups.
* Denotes significance at p < .05.
FIGURE 3. Representative micro-CT scans of debridement versus adipose-derived stem cells (ASCs) 1 deferoxamine (DFO) mandibles demonstrat-
ing superior mineralization at the fracture site in treated mandibles.
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(HIF-1a) pathway. Under normoxic conditions, HIF-1a
undergoes prolyl-hydroxylation in a reaction requiring
iron as a cofactor, ultimately leading to its degradation.
Acting as an iron chelator, DFO prevents this degradation
by removing iron from the equation. The sustained pres-
ence of HIF-1a allows for the activation of a transcrip-
tional cascade, upregulating vascular endothelial growth
factor and other angiogenic factors. Utilizing this
approach to augment angiogenesis and subsequent vascu-
larity, investigators have demonstrated the ability to
accelerate normal fracture healing and distraction osteo-
genesis in long bone animal models.27–29 We have uti-
lized this powerful technique to prevent the development
of non-unions in the irradiated rat mandible. We have
demonstrated improved metrics of vascularity, osteocyte
viability, callus mineralization, and biomechanical
strength as follows: 220% increase in vessel number12;
122% increase in osteocyte count14; 53% increase in bone
mineral density13; and 147% increase in ultimate load.13
Collectively, we observed a prevention of non-union
formation by 45% over nontreated controls (non-unions
control 5 22% vs DFO 5 67%) in a model in which
non-unions are the expected outcome.12–14 The present
study represents an extension of our previous line of
inquiry that seeks to treat non-unions once already estab-
lished. In order to do this, we modified our experimental
study design by selecting only animals exhibiting non-
unions and subjecting them to further experimentation, as
previously described.
Although our selection of DFO is based on our prior
promising results concerning the prevention of non-
unions, the addition of ASCs to our current treatment par-
adigm was warranted because of the extent of tissue
necrosis. Tissue necrosis after radiation potentiates the
formation of volumetric voids that may presumably be
filled by introducing viable progenitors to the site of
injury. Recent studies have shown promise in the treat-
ment of radiation tissue injury with lipoaspirate transplan-
tation. ASCs have been hypothesized to target damaged
areas, release angiogenic factors, form new vessels, and
increase tissue oxygenation.40–42 Recent improvements in
isolation techniques and processing mechanisms have
made ASCs an attractive reproducible means for tissue
engineering strategies. ASCs are easily accessible, avail-
able in large numbers, attach and proliferate rapidly in
culture, and have demonstrated the capacity to success-
fully fill critical sized bone defects in calvarial rat mod-
els.22 Levi et al23 demonstrated that ASCs undergo rapid
osteogenic differentiation to successfully ossify critical-
sized mouse calvarial defects. Based on collective obser-
vations, other investigators have posited that even a rela-
tively large sized defect might be successfully repaired
via ASC implantation. Small clinical studies have already
investigated the potential for ASCs to heal defects in the
human skeleton. In fact, successful or expedited healing
of defects in the human mandible, maxilla, and cranium
were reported with the implementation of ASC-based
treatment paradigms.43–45
Our results demonstrate that the combination of the cel-
lular regeneration from ASCs and the angiogenic impact
of DFO efficaciously bolster the treatment of non-unions
developing secondary to a high dose of radiation.
Although 80% of non-unions were healed with debride-
ment alone, the addition of ASCs and DFO allowed for a
remarkable 93% union rate in comparison. Further, our
outcomes of micro-CT and biomechanical testing reveal
that the unions in the treatment group demonstrated
enhanced mineralization and mechanical strength in com-
parison with their nontreated counterparts. These data, in
addition to gross examination of more robust callus for-
mation, indicate that the functionality of these mandibles
may be meaningfully improved with ASC and DFO com-
bination therapy, which may have important clinical rami-
fications. Specifically, radiomorphometric analysis
indicated a 9% increase in both BVF and BMD, as well
as a 26% increase in TMD in the treatment group. Bio-
mechanical tension testing further substantiated the effi-
cacy of combined therapy as demonstrated by significant
improvements in whole bone yield load by 87% and fail-
ure energy by 154% beyond debridement alone. Biome-
chanical enhancements of 51% for ultimate load, 47% for
failure load, and 261% for elastic energy were trending,
but not significant because of large SDs. These data sug-
gest that because of their inferior biomechanical strength,
unions that had only received debridement may be more
susceptible to reinjury.
We wish to address certain limitations to this study that
should be considered when interpreting our findings
within the context of clinical applications. Although we
focused our investigation on the healing of bone, clini-
cally, patients presenting with osteoradionecrosis and
pathologic fractures often undergo extensive debridement
of necrotic tissue, including large sections of soft tissues.
Whereas our results with regard to bony healing are
promising, they do not address the need for soft tissue
reconstruction. We therefore advocate future investigation
of these applications for the enhancement of soft tissue
healing after radiation injury. Second, although our objec-
tive was to investigate the use of a combined therapeutic
approach for the treatment of radiation-induced non-
unions, subsequent studies are necessary to elucidate the
specific etiology of the reconstructive ability of the stem
cells. Currently, it is unclear whether the cells differenti-
ate into osteoblasts and directly grow bone, or differenti-
ate into endothelial cells and contribute to the
vasculature, or produce proregenerative cytokines, or
most likely, a combination of these events. Future studies
aimed at determining the specific mechanism of how
TABLE 2. Biomechanical metrics.
Debridement ASCs 1 DFO p value
Yield in Newtons 35.06 6 14.91 65.39 6 28.55 .015*
Energy in Joules 6.67 6 4.45 16.96 6 11.78 .026*
Ultimate load in
Newtons
50.17 6 22.93 75.82 6 32.03 .066
Failure load in
Newtons
50.17 6 22.93 73.99 6 33.82 .095
Elastic energy
in Joules
2.96 6 3.38 10.70 6 10.92 .057
Abbreviations: ASCs, adipose derived stromal cells; DFO, deferoxamine.
Means 6 SDs for each group. The p values were also given for independent t tests between
the groups.
* Denotes significance at p < .05.
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ASCs incorporate into the irradiated endogenous tissue
will utilize ubiquitously green fluorescent protein-tagged
cells to attempt to track the fate of the implanted stem
cells.
Although these results are promising, it is important to
address the potential clinical use of stem cell therapies
and angiogenic factors in the reconstructive management
of patients with head and neck cancer. We envision the
use of this therapeutic strategy for reconstructive purposes
to be used judiciously in a select group of patients who
have developed sustained bone pathology beyond conven-
tional care and remain cancer free at the time of recon-
struction. It is also important to note that the incidence of
pathologic fractures because of advanced osteoradionecro-
sis is typically a late finding, manifesting even years after
reconstruction.7,39 This disease-free period is advanta-
geous to our treatment paradigm because it temporally
limits any interaction stem cells or angiogenic factors
may have with malignant cells. Last, although antiangio-
genic therapies have been successful in halting the pro-
gression of various tumors, no known studies have
reported an associated incidence linking the development
of tumors to the use of angiogenic therapies or ASCs.
Nevertheless, the results of this experiment demonstrate
promising evidence in an animal model of a combined
alternative therapeutic approach for the treatment of
radiotherapy-induced non-unions. Specifically, quantifi-
able measures of bone density and bone strength are evi-
denced in the rat mandible. Based on our findings, we
support the continued optimization of this promising strat-
egy for translation to the clinical arena, and assert that
the ability to change a radiated environment to allow for
the healing of non-unions would make a substantial con-
tribution to the reconstructive surgeon’s current manage-
ment arsenal.
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